Indolocarbazole

Indolocarbazoles (ICZs) are a class of compounds that are under current study due to their potential as anti-cancer drugs and the prospective number of derivatives and uses found from the basic backbone alone. First isolated in 1977,[1] a wide range of structures and derivatives have been found or developed throughout the world. Due to the extensive number of structures available, this review will focus on the more important groups here while covering their occurrence, biological activity, biosynthesis, and laboratory synthesis.

Structural formula of staurosporine, the first indolocarbazole to be isolated

Chemical classification

Indolocarbazoles belong to the alkaloid sub-class of bisindoles. The most frequently isolated indolocarbazoles are Indolo(2,3-a)carbazoles; the most common subgroup of the Indolo(2,3-a)carbazoles are the Indolo(2,3-a)pyrrole(3,4-c)carbazoles. These can be divided into two major classes - halogenated (chlorinated) with a fully oxidized C-7 carbon with only one indole nitrogen containing a β-glycosidic bond and the second class consists of both indole nitrogen glycosylated, non-halogenated, and a fully reduced C-7 carbon.

Occurrence

The first isolated ICZ, dubbed staurosporine (STA) was in 1977 from a culture of Streptomyces staurosporeus found in a soil sample from Iwate Prefecture, Japan.[2] The proper stereochemistry was not proven until 1994. Over the course of the next decade, further study of the compound showed some fungi inhibition, hypotensive activity, and most importantly, a broad protein kinase inhibitor. The next landmark discovery came with the detection of rebeccamycin (REB) in a sample of Lechevalieria aerocolonigenes, again in soil, but this time in a sample from Panama. REB was found to act against leukemia and melanoma in mice, and also against human adenocarcinoma cells.[3]

Since 1977, ICZs have been discovered all over the world in actinomycetes, bacteria commonly found in soil. Numerous forms have tested positive for anti-tumor activity, such as 7-hydroxy-STA and 7-oxo-STA2. Some of the strains from which ICZ compounds have been found are Actinomadura melliaura in Bristol Cove, California, Streptomyces hygroscopicus in Numazu Prefecture, Japan, Micromonospora sp. L-31-CLO-002 from Fuerteventura Island, Canary Islands, Spain, and Actinomadura sp. Strain 007 from Jiaozhou Bay, China. The wide distribution of the various strains that produce these compounds is not surprising due to the number of properties these compounds can take on with limited functionalization on the specie’s part.

In addition to actinomycetes, ICZs have been found in slime molds (myxomycetes), blue-green algae (cyanobacteria, and marine invertebrates. Like the ones derived from actinomycetes, the ones found in myxomycetes cover an expansive range of derivatives and functionalizations. Two of the more important ones to date have been Arcyriacyanin A, which was found to inhibit a panel of human cancer cells by effecting PKC and protein tyrosine kinase, and lycogalic acid dimethyl ester A (found in Tokushima, Japan from Lycogala epidendrum), which showed strong antiviral activity. A few of the strains of myxomycetes studied are Arcyria ferruginea and Arcyria cinerea, both from Kochi Prefecture, Japan.[1]

Three species of cyanobacteria has been found to produce ICZ compounds. Nostoc sphaericum from Manoa Hawaii, Tolypothrix tjipanasensis from Vero Beach, Florida, and Fischerella ambigua strain 108b from Leggingen, Switzerland. An interesting note on the first two is that many of the ICZ derived from them do not have the annelated pyrrolo[3,4-c] unit.[4]

The final major group in which ICZs are found are various marine invertebrates. Three species of tunicate, one mollusk, one flatworm, and one sponge have been discovered in places ranging from Micronesia to New Zealand. Testing for further invertebrate production is ongoing by both genetic and phylum-based studies.[1]

Biological activity

Indolocarbazoles have been found to exhibit a wide range of activities, which makes their range of presence in nature unsurprising. Because of this variety, the following section will examine their modes of action in bacterial and mammalian cells independently, with special attention paid to cancer cell effects.

The general modes of action found in mammalian cells are inhibition of protein kinases, inhibition of eukaryotic DNA topoisomerase, and intercalative binding to DNA. The number of protein kinases thought to exist in the human genome exceeds six hundred,[5] making a nanomolar inhibitor such as STA extremely useful for both treatment of various diseases and study of protein kinases in a variety of functions. Since this discovery, a vast effort has been undergone to make highly specific STA and REB derivatives.[6] One of the major lessons learned from initial research on STA was the development of the pharmacophore model for a protein kinase inhibitor in which a bidentate hydrogen donating system flanked by various hydrophobic groups inserts into the binding site. The information derived from this original pharmacophore has led to the synthesis of highly specific inhibitors against a number of protein kinases, including PKC, cyclin-dependent kinases, G-protein coupled receptor kinases, tyrosine kinase, and cytomegalovirus pUL97 protein.[7]

Topoisomerase I and II cleave and relegate one and two sides of a DNA strand, respectively, and are consequently vital parts of cell reproduction. Studies have found that in REB-like structures, the imide function of the pyrrole segment acts to interact with Topoisomerase I, the main carbon backbone acts as an intercalative inhibitor, and the sugar moiety undergoes DNA groove binding.[6] The latter two actually act in unison due to the three-dimensional structure of a glycosylated REB molecule.[3] The Top1 inhibitor section binds to cleavable DNA-Top1 complexes so as to prevent the relegation step. Because of this, sensitivity is based on quantity of Top1 present, making cells undergoing constant reproduction and growth (namely tumor cells) most vulnerable.

At this point, bacterial inhibition of Top1 has not been founding using ICZs. Because of this, it is thought that most of the anti-cell growth function of ICZs comes from inhibition of various protein kinase groups and intercalative DNA binding.[8][9] Studies on Streptomyces griseus with in vitro protein labelling have led to inhibition of a wide range of cellular functions. This led to the theory that there were several eukaryotic protein kinases present required for secondary metabolism.[10]

Biosynthesis

Unfortunately, only biosynthesis of REB, STA, and K252a have been studied in depth. This section will emphasize the REB pathway due to how well studied it is. The pathway begins with the modification of L-tryptophan to 7-chloro-L-tryptophan. This is done by catalysis using RebH in vitro halogenation and RebF (a flavin reductase) to provide FADH2 for the halogenase.[11] RebO (a tryptophan oxidase) then deaminates, after which it is further reacted with another one of itself and RebD (a heme containing oxidase). This forms the majority of the carbon backbone, which then undergoes decarboxylative ring closure using RebC and RebP. A glycosylation occurs using RebG and NDP-D-glucose, which finally goes through methylation by RebM.[12][13][14][15][16][17] These latter tailoring enzymes have been noted as permissive in terms of both aglycons/acceptors and glycosyl/alkyl donors.[18][19][20] A parallel pathway has been put forth for the structurally related disaccharide-substituted indolocarbazole AT2433, the aminopentose of which is also found appended to the 10-membered enediyne calicheamicin.[21]

Information for this pathway, along with those of K252a and STA,[22] was derived from information on known genes, enzymes, and intermediates. The two types of studies done on these pathways are in vivo studies of gene disruption of L. aerocolonigenes or recombinant strains of S. albus.[1] The second type of experiment consisted of in vitro experiments done on cell extracts.

Synthesis

Laboratory synthesis of ICZs has been a topic of great interest since their discovery. Unfortunately, due to the somewhat complex nature of the molecule and the high level of reactivity of carbons on indole molecules, a facile high yield synthesis has yet to be found. Despite this, there have been many ways found to produce this compound in its various forms.[23] Of special interest is one of the better REB syntheses, found in 1999. The process begins by producing 7-chloroindole-3-acetamide by treating 7-chloroindole with a series of reagents, shown farther down. This molecule is then glycosylated and reacted with methyl 7-chloroindole-3-glyoxylate to produce an intermediate that goes on to stabilize into the final product. While this process is one of the better ones to date, it is still work and time intensive, going through 12 total steps and only yielding 12%.[24]

Further developments

Ever since the birth of ICZ research in the late seventies, the field has been burgeoning with continued advances in both technology and organic chemistry techniques. While only a handful of ICZ based compounds have made it past stage II clinical trials, the sheer variety that these molecules can take on leaves much still unexplored territory. Of particular recent interest in synthesis techniques is the use of palladium based catalysts, which have been found to be excellent activators for use in formation of carbon-carbon bonds.[25][26]

References
  1. Sanchez C.; Mendez C.; Salas J. A. (2006). "Indolocarbazole natural products: occurrence, biosynthesis, and biological activity". Nat. Prod. Rep. 23 (6): 1007–1045. doi:10.1039/b601930g. PMID 17119643.
  2. Wada Y.; Nagasaki H.; Tokuda M.; Orito K. (2007). "Synthesis of N-protected staurosporinones". J. Org. Chem. 72 (6): 2008–14. doi:10.1021/jo062184r.
  3. Long Byron H.; Rose William C.; Vyas Dolatrai M.; Matson James A.; Forenza S. (2002). "Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles". Curr. Med. Chem. Anti-Cancer Agents. 2 (2): 255–266. doi:10.2174/1568011023354218.
  4. Knubel G.; Larsen L. K.; Moore R. E.; Levine I. A.; Patterson G. M. L. (1990). "Cytotoxic, antiviral indolocarbazoles from a blue-green alga belonging to the Nostocaceae". J. Antibiot. 43 (10): 1236–1239. doi:10.7164/antibiotics.43.1236.
  5. Manning G.; Whyte D. B.; Martinez R.; Hunter T.; Sudarsanam S. (2002). "The Protein Kinase Complement of the Human Genome". Science. 298 (5600): 1912–1916, 1933–1934. Bibcode:2002Sci...298.1912M. doi:10.1126/science.1075762. PMID 12471243.
  6. Prudhomme M (2004). "Biological targets of antitumor indolocarbazoles bearing a sugar moiety". Curr. Med. Chem. 4 (6): 509–521. doi:10.2174/1568011043352650.
  7. Zimmermann A.; Wilts H.; Lenhardt M.; Hahn M.; Mertens T. (2000). "Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase". Antiviral Res. 48: 49–60. doi:10.1016/s0166-3542(00)00118-2.
  8. Iwai Y.; Omura S.; Li Z. (1994). "Indolocarbazole alkaloids produced by microorganisms. Staurosporine as the main". Kagaku Seibutsu. 32: 463–469. doi:10.1271/kagakutoseibutsu1962.32.463.
  9. Pereira E. R., Fabre S., Sancelme M., Prudhomme M. (1995). "Antimicrobial activities of indolocarbazole and bis-indole protein kinase C inhibitors. II. Substitution on maleimide nitrogen with functional groups bearing a labile hydrogen". J. Antibiot. 48 (8): 863–868. doi:10.7164/antibiotics.48.863.CS1 maint: multiple names: authors list (link)
  10. Lum P. Y.; Armour C. D.; Stepaniants S. B.; Cavet G.; Wolf M. K.; Butler J. S.; Hinshaw J. C.; Garnier P.; Prestwich G. D.; Leonardson A.; Garrett-Engele P.; Rush C. M.; Bard M.; Schimmack G.; Phillips J. W.; Roberts C. J.; Shoemaker D. D. (2004). "Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes". Cell. 116: 121–137. doi:10.1016/s0092-8674(03)01035-3. PMID 14718172.
  11. Bitto, E; Huang, Y; Bingman, CA; Singh, S; Thorson, JS; Phillips GN, Jr (1 January 2008). "The structure of flavin-dependent tryptophan 7-halogenase RebH". Proteins. 70 (1): 289–93. doi:10.1002/prot.21627. PMID 17876823.
  12. Zhang G.; Shen J.; Cheng H.; Zhu L.; Fang L.; Luo S.; Muller Mark T.; Lee Gun E.; Wei L.; Du Y.; Sun D.; Wang Peng G. (2005). "Syntheses and biological activities of rebeccamycin analogues with uncommon sugars". J. Med. Chem. 48 (7): 2600–2611. doi:10.1021/jm0493764.
  13. Sanchez C.; Zhu L.; Brana A. F.; Salas A. P.; Rohr J.; Mendez C.; Salas J. A. (2005). "Combinatorial biosynthesis of antitumor indolocarbazole compounds". Proc. Natl. Acad. Sci. USA. 102: 461–466. Bibcode:2005PNAS..102..461S. doi:10.1073/pnas.0407809102. PMC 544307. PMID 15625109.
  14. Sanchez C.; Brana A. F.; Mendez C.; Salas J. A. (2006). "Reevaluation of the violacein biosynthetic pathway and its relationship to indolocarbazole biosynthesis". ChemBioChem. 7 (8): 1231–1240. doi:10.1002/cbic.200600029.
  15. Nishizawa T.; Gruschow S.; Jayamaha D. H.; Nishizawa-Harada C.; Sherman D. H. (2006). "Enzymatic assembly of the bis-indole core of rebeccamycin". J. Am. Chem. Soc. 128 (3): 724–725. doi:10.1021/ja056749x. PMID 16417354.
  16. Hyun, CG; Bililign, T; Liao, J; Thorson, JS (3 January 2003). "The biosynthesis of indolocarbazoles in a heterologous E. coli host". ChemBioChem: A European Journal of Chemical Biology. 4 (1): 114–7. doi:10.1002/cbic.200390004. PMID 12512086.
  17. Singh, S; McCoy, JG; Zhang, C; Bingman, CA; Phillips GN, Jr; Thorson, JS (15 August 2008). "Structure and mechanism of the rebeccamycin sugar 4'-O-methyltransferase RebM". The Journal of Biological Chemistry. 283 (33): 22628–36. doi:10.1074/jbc.m800503200. PMC 2504894. PMID 18502766.
  18. Zhang, C; Albermann, C; Fu, X; Peters, NR; Chisholm, JD; Zhang, G; Gilbert, EJ; Wang, PG; Van Vranken, DL; Thorson, JS (May 2006). "RebG- and RebM-catalyzed indolocarbazole diversification". ChemBioChem: A European Journal of Chemical Biology. 7 (5): 795–804. doi:10.1002/cbic.200500504. PMID 16575939.
  19. Zhang, C; Weller, RL; Thorson, JS; Rajski, SR (8 March 2006). "Natural product diversification using a non-natural cofactor analogue of S-adenosyl-L-methionine". Journal of the American Chemical Society. 128 (9): 2760–1. doi:10.1021/ja056231t. PMID 16506729.
  20. Singh, S; Zhang, J; Huber, TD; Sunkara, M; Hurley, K; Goff, RD; Wang, G; Zhang, W; Liu, C; Rohr, J; Van Lanen, SG; Morris, AJ; Thorson, JS (7 April 2014). "Facile chemoenzymatic strategies for the synthesis and utilization of S-adenosyl-(L)-methionine analogues". Angewandte Chemie International Edition in English. 53 (15): 3965–9. doi:10.1002/anie.201308272. PMC 4076696. PMID 24616228.
  21. Gao, Q; Zhang, C; Blanchard, S; Thorson, JS (July 2006). "Deciphering indolocarbazole and enediyne aminodideoxypentose biosynthesis through comparative genomics: insights from the AT2433 biosynthetic locus". Chemistry & Biology. 13 (7): 733–43. doi:10.1016/j.chembiol.2006.05.009. PMID 16873021.
  22. Makino M.; Sugimoto H.; Shiro Y.; Asamizu S.; Onaka H.; Nagano S. (2007). "Crystal structures and catalytic mechanism of cytochrome P450 StaP that produces the indolocarbazole skeleton". Proc. Natl. Acad. Sci. USA. 104 (28): 11591–11596. Bibcode:2007PNAS..10411591M. doi:10.1073/pnas.0702946104. PMC 1913897. PMID 17606921.
  23. Gu R.; Hameurlaine A.; Dehaen W. (2007). "Facile one-pot synthesis of 6-monosubstituted and 6,12-disubstituted 5,11-dihydroindolo[3,2-b]carbazoles and preparation of various functionalized derivatives". J. Org. Chem. 72 (19): 7207–7213. doi:10.1021/jo0711337.
  24. Faul M. M.; Winneroski L. L.; Krumrich C. A. (1999). "Synthesis of Rebeccamycin and 11-Dechlororebeccamycin". J. Org. Chem. 64 (7): 2465–2470. doi:10.1021/jo982277b.
  25. Trost B. M., Krische M. J., Berl V., Grenzer E. M. (2002). "Chemo-, Regio-, and Enantioselective Pd-Catalyzed Allylic Alkylation of Indolocarbazole Pro-aglycons". Org. Lett. 4 (12): 2005–2008. doi:10.1021/ol020046s.CS1 maint: multiple names: authors list (link)
  26. Saulnier M. G., Frennesson D. B., Deshpande M. S., Vyas D. M. (1995). "Synthesis of a rebeccamycin-related indolo[2,3-a]carbazole by palladium(0) catalyzed polyannulation". Tetrahedron Lett. 36 (43): 7841–7844. doi:10.1016/0040-4039(95)01644-w.CS1 maint: multiple names: authors list (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.